Design of Lean to Roof Steel Trusses with Hollow Circular tube using IS 875 (part-III):2015 & IS 800:2007

At present, SP-38:1987 is available which provides design for lean to roof type trusses and pitch roof trusses. The design of lean to roof truss has been carried out as per IS 800:1984 IS 875 (Part-III):1964. Afterwards IS 800:1984 is revised in 2007, which is based on limit state method. Also, IS 875 (Part-III) is updated in 1987 and then in 2015 considering climate changes and economical parameters. Accordingly, study has been done to revise the design of trusses given in SP-38:1987. In the present study, design and comparison of lean to roof type truss with steel circular hollow tube section have been carried out using IS 875 (Part-III):2015 and IS 800:2007 limit state method using STAAD Pro. and their results compared with SP-38:1987 results. This study includes lean to roof truss system considering different parameters like span, spacing of truss, slope of roof and wind zones with all cases of wind load. At the end, a compiled report will be prepared, which will be helpful to design engineers to provide economic, easier, faster approach for designing of steel trusses

Loop Amplitudes in the Coulomb Branch of N=4\mathcal{N}=4 Super-Yang-Mills Theory

We study four point loop amplitudes at an arbitrary point in the Coulomb branch of $\mathcal{N}=4$ super-Yang-Mills theory. We study two particle unitary cuts up to four loop order. We explicitly verify that bubble and triangle graphs do not contribute at one loop level and show that the results hold at higher loop level as well. We also write down an all loop recursion relation for two particle reducible graphs for four point amplitudes.Comment: Two references are added. One footnote is added in the discussion sectio

Estimating the use of Dexmedetomidine in nerve repair surgeries requiring intraoperative peripheral nerve stimulation

Background & Aims: Dexmedetomidine has no interference with neurophysiologic monitoring, making it a useful adjunct in the nerve repair surgeries. The aim of study is to evaluate effectiveness of dexmedetomidine in providing adequate sedation for conducting nerve repair surgeries. Methods: This study was conducted among 20 patients who undergoing nerve repair surgery. A loading dose of dexmedetomidine 1mcg/kg was given over 10 minutes. Anaesthesia was induced with IV propofol (1.5-2 mg/kg) and maintained by IV infusion of dexmedetomidine at 0.2–0.7 μ/kg/hr. Heart rate, blood pressure, oxygen saturation, EtCO2, Ramsay sedation score(RSS), duration of surgery, VAS and modified aldrette score were monitored. The data was analyzed with Epi info version 7.1. Comparison of continuous data were analysed with T test. P value less than 0.05 was considered as significant. Results: All patients were sedated (RSS=6) and haemodynamic stable.Duration of surgery was short (57.2±2.4min). There were no major complications. Average 186.7 ± 7.22 mg propofol was used in 1 hour of surgery. Isoflurane dial concentration was 1.0 ± 0.14 %. Conclusions: Dexmedetomidine is safe and effective adjunct to inhalational agents for maintenance of anaesthesia without using non depolarising muscle relaxants during nerve repair surgeries

Neoadjuvant Radiation with Concurrent 5-FU Resulting in Complete Pathologic Response in Stage IIIB Squamous Cell Carcinoma of the Urethra

Squamous cell carcinoma (SCC) of the urethra is a rare malignancy, comprising less than 1% of all malignancies. The annual age-adjusted incidence of urethral SCC is 4.3 per million in men and 1.5 per million in women. Due to the rarity of the disease, there are a limited number of prospective randomized controlled trials to evaluate the optimal management of locally advanced urethral SCC. Here, we present the case of a 47-year-old man with stage IIIB urethral squamous cell cancer that showed complete clinical and pathologic response to neoadjuvant chemoradiation with only 5-flurouracil after incomplete response to traditional chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP)

Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron

Summary: The pairing of antibody genes IGHV2-5/IGLV2-14 is established as a public immune response that potently cross-neutralizes SARS-CoV-2 variants, including Omicron, by targeting class-3/RBD-5 epitopes in the receptor binding domain (RBD). LY-CoV1404 (bebtelovimab) exemplifies this, displaying exceptional potency against Omicron sub-variants up to BA.5. Here, we report a human antibody, 002-S21B10, encoded by the public clonotype IGHV2-5/IGLV2-14. While 002-S21B10 neutralized key SARS-CoV-2 variants, it did not neutralize Omicron, despite sharing >92% sequence similarity with LY-CoV1404. The structure of 002-S21B10 in complex with spike trimer plus structural and sequence comparisons with LY-CoV1404 and other IGHV2-5/IGLV2-14 antibodies revealed significant variations in light-chain orientation, paratope residues, and epitope-paratope interactions that enable some antibodies to neutralize Omicron but not others. Confirming this, replacing the light chain of 002-S21B10 with the light chain of LY-CoV1404 restored 002-S21B10’s binding to Omicron. Understanding such Omicron evasion from public response is vital for guiding therapeutics and vaccine design

Status of the ITER Ion Cyclotron H&CD

The ITER Ion Cyclotron Heating and Current Drive system (IC H&CD) is designed to deliver 20MW to a broad range of plasma scenarios between 40 and 55MHz, during very long pulses. It consists of two broadband equatorial port plug antennas, their pre-matching and matching systems, transmission lines, Radio Frequency (RF) Sources and High Voltage Power Supplies. The overall project schedule has been revised and agreed by ITER Council; it re-integrates the second antenna and its power supplies in construction baseline and sets the dates for progressive installation with DT phase planned in 2035. Recent progress on ICRF subsystems is reported, covering design evolution, qualification of test articles and specific R&D results in domestic agencies, suppliers, associated laboratories and IO

Status of the ITER Ion Cyclotron H&CD

The ITER Ion Cyclotron Heating and Current Drive system (IC H&CD) is designed to deliver 20MW to a broad range of plasma scenarios between 40 and 55MHz, during very long pulses. It consists of two broadband equatorial port plug antennas, their pre-matching and matching systems, transmission lines, Radio Frequency (RF) Sources and High Voltage Power Supplies. The overall project schedule has been revised and agreed by ITER Council; it re-integrates the second antenna and its power supplies in construction baseline and sets the dates for progressive installation with DT phase planned in 2035. Recent progress on ICRF subsystems is reported, covering design evolution, qualification of test articles and specific R&D results in domestic agencies, suppliers, associated laboratories and IO